Ribavirin (Systemic)



General

Pronunciation

(rye ba VYE rin)

Brand Names: U.S.

  • Copegus [DSC]
  • Moderiba
  • Moderiba 1200 Dose Pack
  • Moderiba 800 Dose Pack
  • Rebetol
  • Ribasphere
  • Ribasphere RibaPak
  • RibaTab [DSC]

Indications

Use: Labeled Indications

Oral capsule: In combination with interferon alfa 2b (pegylated or nonpegylated) injection for the treatment of chronic hepatitis C in interferon alfa-naive or experienced patients ≥3 years of age with compensated liver disease. Patients likely to fail re-treatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, or those with genotype 1 infection.

Oral solution: In combination with interferon alfa-2b (pegylated or nonpegylated) injection for the treatment of chronic hepatitis C in interferon alfa-naive or experienced patients ≥3 years of age with compensated liver disease. Patients likely to fail re-treatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, or those with genotype 1 infection.

Oral tablet: In combination with peginterferon alfa-2a for the treatment of patients ≥5 years of age with chronic HCV infection who have compensated liver disease and have not previously been treated with interferon alpha.

Guideline recommendations: Peginterferon and ribavirin, without additional preferred HCV antiviral agent(s), is not recommended for hepatitis C virus (HCV) (regardless of genotype) in HCV adult treatment guidelines (treatment-naive or treatment-experienced). In addition, nonpegylated interferons are not included in any recommended HCV treatment regimens. Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b) to combine with oral ribavirin and additional preferred HCV antiviral agent(s); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a (AASLD/IDSA 2015). Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations.

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

×